Gyre Therapeutics Inc (GYRE)

In March 2026, Gyre Therapeutics reported a 10.2% year-over-year revenue increase to $116.6 million for 2025 and provided 2026 revenue guidance of $100.5 million to $111.0 million. The company announced an agreement to acquire Cullgen for approximately $300 million, expected to close in the second quarter of 2026. Gyre aligned with China's CDE for conditional approval and priority review eligibility for Hydronidone, with an NDA submission expected in the first half of 2026, and completed patient enrollment in a Phase 3 pirfenidone trial for pneumoconiosis. Over the past year, Gyre Therapeutics' stock has underperformed both the US Biotechs industry and the broader US Market.

Information regarding demand seasonality for Gyre Therapeutics, Inc.'s products and services was not found in the provided search results.

Gyre Therapeutics, Inc., headquartered in San Diego, California, is a biopharmaceutical company focused on developing and commercializing small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis, operating within the biotechnology industry. Its lead candidate, Hydronidone (F351), targets liver fibrosis and is in Phase 3 trials in China and under IND application in the US. ETUARY (Pirfenidone) is an approved anti-fibrotic drug in China for IPF and is undergoing Phase 3 trials for other indications. Avatrombopag (Contiva) and Nintedanib (Etorel) are generic drugs approved in China. F573 is in Phase 2 trials, while F528 and F230 are preclinical products.

Gyre Therapeutics has a dual geographic focus with headquarters in San Diego, California, primarily focused on Hydronidone development for MASH-associated liver fibrosis. It also has a significant presence in China through Beijing Continent (Gyre Pharmaceuticals), commercializing drugs like ETUARY and advancing its pipeline.

Information specifically detailing Gyre Therapeutics, Inc.'s brand reputation or events affecting it in the past year was not found in the provided search results.

Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc., with GNI Group, a Japanese drugmaker, as the parent company. Specific major institutional and individual owners beyond this relationship were not detailed.